Introduction Psoriatic arthritis (PsA) with axial involvement presents a unique treatment challenge due to diagnostic ambiguity and limited targeted options (1). Upadacitinib (UPA), a selective JAK inhibitor, demonstrated significant and sustained improvement in axial symptoms and disease activity in the SELECT-PsA 1 and 2 trials (1). The following
12 Reached
Acute Renal Failure in Child Due to High Dose of Indomethacin
685 Reached6 Comments
Woman presented with Fever of Unknown Origin
7716 Reached93 Comments19 Likes
How Physicians Should Manage Stress?
35294 Reached152 Comments203 Likes
Fremanezumab for Prevention and Treatment of Migraine
390 Reached13 Comments11 Likes
Rubella Syndrome in Neonate
1394 Reached12 Comments9 Likes